Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Repligen Corp (NQ: RGEN ) 126.06 -0.53 (-0.42%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Repligen Corp < Previous 1 2 3 4 5 6 Next > Cancer Therapy Novocure Stock Flashes Renewed Technical Strength April 14, 2021 Novocure stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 67 to 92. Via Investor's Business Daily 10 Biggest Price Target Changes For Monday April 12, 2021 Canaccord Genuity raised the price target on Tesla, Inc. (NASDAQ: TSLA) from $419 to $1071. Tesla shares rose 1.5% to $687.13 in pre-market trading. Keybanc lowered the price... Via Benzinga Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge May 01, 2021 Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... Via Benzinga Exposures Product Safety Repligen Stock Gets Relative Strength Rating Upgrade With Earnings Due April 28, 2021 A Relative Strength Rating upgrade for Repligen shows improving technical performance. Will it continue? Via Investor's Business Daily Medical Device Maker Quanterix Sees Relative Strength Rating Rise To 86 April 27, 2021 On Tuesday, Quanterix stock hit an important technical milestone, with its Relative Strength (RS) Rating rising into to 86, up from 80 the day before. Via Investor's Business Daily Align Technology Nears Buy Point With Earnings Due April 21, 2021 Align Technology is near a possible buy zone ahead of its next quarterly earnings report, expected on or around April 28. Via Investor's Business Daily Cancer Therapy Novocure Stock Still On A High As It Clears Technical Benchmark April 21, 2021 Cancer therapy Novocure stock had its Relative Strength (RS) Rating upgraded from 90 to 93 Wednesday. It's also an IBD 50 member. Via Investor's Business Daily < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.